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1 Introduction 
Lung cancer is the most common form of cancer worldwide. Statistics show an annual 
increase of 0.5% in fatalities associated with lung cancer. It is the most common form of 
death from cancer in Germany (Becker 2010 – [Epidemiology of lung cancer.]). Many 
experts predict that by the year 2020 lung cancer will account for 50% of cancer-related 
deaths.  
One problem is the late diagnosis, in order that the prognosis for most patients remains 
poor. In most of the cases the five-year survival rate amounts to 15%. Nevertheless, 
advances are being made in the battle to combat lung cancer such as research focused 
on molecular-targeted therapies. 
 
1.1 Lung cancer 
1.1.1 Lung cancer pathology 
Tumors arising from respiratory epithelium bronchi, bronchioles and alveoli are called 
lung cancer. According to the World Health Organization (WHO), lung cancer is the 
leading cause of cancer death in men and woman. 
There are two classes of lung cell carcinoma: small cell lung carcinoma (SCLC) and 
Non-small cell lung carcinoma (NSCLC) with its varieties of squamous, 
adenocarcinoma and large cell carcinoma. It is important to determine whether a tumor 
is SCLC or NSCLC for both prognostic and therapeutic reasons. The correct histologic 
diagnosis needs to be done by an experienced pathologist. 
The odds of surviving lung cancer are low, particulary as SCLC and NSCLC require 
different treatments. The choice of treatment depends on the stage of the disease; that is, 
on whether it is just commencing, or is already mature. 
Diagnosis of lung cancer and staging comprises the following: pulmonary X-rays, CT 
scans of the thorax and upper abdomen, bronchoscopy and; in selected cases, 
mediastinoscopy. The classification is based primarily on the results of these 
examinations. The TNM International Staging System is frequently used for NSCLC 
classification. TNM stands for tumor size (T), regional node involvement (N), and 
presence or absence of distant metastasis (M). The different stage groups are defined by 
combining those three factors. 
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The TNM classification is not used for SCLC. There is a two-stage system including 
limited-stage disease and extensive-stage disease. 
Limited-stage is defined as a disease confined to regional lymph nodes, one hemithorax 
and mediastinum. 
Extensive-stage disease is used for all other SCLC stadiums exceeding those bounds. 
1.1.2 Classification 
Cancer can occur in all kinds of tissue, i.e. soft tissue, mesothelium, lymphatics, 
epithelium or miscellaneous. If there are mixed tumors they need to be named according 
to the cell form that is most exposed. 
Epithelial tumors are classified into two major groups: SCLC and NSCLS. 
15% - 20% of the cases are SCLC. This form mainly starts in the central bronchus and 
grows rapidly. 
NSCLC is classified into three types: adenocarcinoma, squamous cell cancer, and large-
cell carcinoma. NSCLC accounts for 75% - 80% of the epithelial lung cancer cases. 
Adenocarcinoma:  
This is usually localised in the periphery of the lung; it is most commonly found 
amongst non-smokers. Adenocarcinoma usually accounts for 35% - 40 % of 
lung cancer cases. 
Squamous cell cancer: 
These have a growth rate slower than that of adenocarcinoma. They start in 
larger airways like SCLC. Because of their slow growth, the size of these tumors 
varies when exposed. 
Large-cell carcinoma: 
These account for about 10%-15% of lung cancers. They are characterised by 
fast growth and their occurrence near the surface of the lungs.  
 
There are other types of lung cancers, but these only cause less than 5% of all the lung 
cancer cases. This group of rarely represented cancers includes the following: carcinoid 
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tumor, sarcomatoid carcinoma and other soft tissue tumor, adenoid cystic carcinoma, 
mucoepidermoid carcinoma and other unspecified carcinomas (Harrisons Principles of 
Internal Medicine, 17th edition, p. 551, table 85-1 according to WHO classification). 
For research purpose cell lines like A549 or H1437 (human adenocarcinoma), H226 
(squamous cell carcinoma) and H460 or H661 (large-cell carcinoma) are used. In this 
experimental work we decided to take A549 cells to represent the largest subgroup of 
NSCLC.  
1.1.3 Risk factors 
Patients with lung cancer of all histologic types are current or former smokers in 75% - 
90% of men and 30% - 60% of women. (Becker 2010 – [Epidemiology of lung cancer.]) 
Even passive smoking is considered a common cause of cancer. (IARC Working Group 
2007- Smokeless tobacco and some tobacco-specific) 
In general cancer is the final step in a sequence of structural and morphological changes 
that transform normal cells into malignant cells and emerge over several years. There 
are, potentially, numerous causes for the occurrence of lung cancer: genetic lesions, 
including the activation of dominant oncogenes and inactivation of tumor-suppressor or 
tumor-recessive oncogenes; the immune system, cellular irritation caused by asbestos, 
radon and many other environmental factors (DGAUM). Proto-oncogenes are 
responsible for controlling cell cycle control, programming cell death, regulating 
growth, and terminal differentiation. Faulty expression of the genetic translocations 
would cause mutations or DNA amplification, which would, consequently, result in 
tumorigenesis. The best known tumor-supressor gene is p53. In usually modified types 
of cancer, it is downregulated or defective, like most of tumor suppressor genes and 
unlike the classical oncogenes. Tumor development continues by obtaining support 
from surrounding stromal cells, and attracting new blood vessels to bring essentials like 
oxygen and nutrients, avoiding immune detection and thus paveing the way for 
metastasis. 
By determining the stage and type of cancer, it is possible to treat the disease with 
certain chemotherapeutic agents, surgery, radiation therapy, or a combination of these 
treatments. 
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1.2 Therapy 
1.2.1 Surgery 
The treatment of NSCLC and SCLC includes the following three surgical procedures 
for pulmonary resection: lobectomy, wedge resection and pneumonectomy. 
Surgical resection is only used to treat SCLC, when the patients have neither a locally 
advanced disease nor distant metastases. 
Pulmonary resection is the treatment of choice in patients with NSCLC stages IA, IB, 
IIA and IIB provided that they can tolerate the operation (Prasse, Waller et al. 2010 – 
Lung cancer from the perspective). 
1.2.2 Chemotherapy 
Multimodal therapy has become the norm for regionally advanced disease, and patients 
with advanced and metastatic disease are candidates for palliative chemotherapy, for 
which there is documented evidence of improvements in survival and quality of life 
measures.  
Cisplatin, a strong and widely used chemotherapy drug, is commonly used in both 
NSCLC and SCLC. In NCSLC cisplatin in combination with vinorelbine provided a 
marginally better benefit than other drug combinations. (Arriagada, Bergman et al. 2004 
- Cisplatin-based adjuvant chemotherapy in patients) 
The combination of cisplatin plus etopsid or topotecan is used for the treatment of 
SCLC, for NSCLC, cisplatin plus etopsid or vinorelbine is used. 
1.2.3 Radiation therapy 
As described, surgery is not an option when patients cannot tolerate the operation. In 
that case radiation therapy is adapted to the tumor tissue. 3D conformal radiation 
therapy is a method to get the highest dose of radiation clearly defined at tumor tissue 
without damaging much of the surrounding healthy tissue. Even if the tumor is too 
widespread for surgery and at this stage no distant metastases were found, patients 
profit from this treatment (Zierhut, Bettscheider et al. 2001 – Radiation therapy of stage 
I). 
1.2.4 Targeted therapy 
Commonly used procedures: chemotherapy, radiation therapy, and surgery, all have 
limited success. Consequently, researchers have been focusing on alternative 
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approaches that attack molecular mechanisms in tumorgenesis, such as mechanisms 
related to the cell cycle, angiogenesis, and protein degradation. 
Currently, cetuximab, an anti-EGFR monoclonal antibody, and EGFR tyrosine kinase 
inhibitors such as gefitinib and erlotinib are used in NSCLC therapies. Bevacizumab, an 
inhibitor targeted specifically at angiogenesis, is also used for treating this kind of 
cancer. Furthermore there are powerful multitargeted agents to treat non-small cell lung 
cancer, i.e. sunitinib and sorafenib. Sunitinib and sorafenib are multi-tyrosine kinase 
inhibitors with antitumor and angiogenetic activities (Katzel, Fanucchi et al. 2009 – 
Recent advances of novel targeted). 
It is possible to increase the survival in patients with advanced non-small cell lung 
cancer by using cetuximab (Pirker, Pereira et al. 2009 – Cetuximab plus chemotherapy 
in patients). 
For patients with advanced or recurrent non-small cell lung cancer, bevacizumab, 
together with carboplatin and paclitaxel, shows a higher success rate, longer median 
time to progression and a slightly better increase in survival than in a control group not 
given bevacizumab in therapy in a randomized phase II study (Johnson, Fehrenbacher et 
al. 2004 – Randomized phase II trial comparing). 
Gefitinib is also a well-tolerated agent in the treatment of NSCLC (Tiseo, Bartolotti et 
al. 2010 – Emerging role of gefitinib). 
 
1.3 Growth factors 
Growth factors include a group of polypeptides which transfer a signal from one cell to 
another cell by using a specific receptor in the membrane. Some of their principal tasks 
are differentiation, survival and proliferation. In addition, they induce a variety of 
intracellular processes. Currently, several of the signal transductions and their 
associated growth factors platelet-derived growth factor (PDGF), epidermal growth 
factor (EGF), vascular endothelial growth factor (VEGF) and transforming growth 
factor (TGF) are known. They operate by binding to tyrosine kinases receptors. 
A possible solution for the treatment of NSCLC is the blocking of the above receptors. 
1.3.1 Platelet-derived growth factor 
Platelet-derived growth factor receptors (PDGFR) are cell surface tyrosine kinase 
receptors. There are two important subunits, PDGFR-alpha and PDGFR-beta, for cell 
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differentiation, cell growth, development and cell proliferation are encoded in different 
genes. Presently PDGF-C and PDGFR-D are established. There are five isoforms of the 
PDGF ligand: PDGF-AA, PDGF-AB, PDGF-BB PDGF-CC and PDGF-DD. Some of 
them can specifically bind to and activate PDGFR-alpha or PDGFR-beta, while others 
can stimulate heterodimeric PDGFRalpha/beta complexes. 
When the ligand binds to the receptor, a dimerization of the intracellular part follows. 
This is the important requirement for the following transphosphorylation, activation of 
intracellular proteins and creation of binding sites for downstream well-characterized 
signaling pathways, e.g. RAS/MAPK, JAK/STAT and P13K (Balottin, Nicoli et al. 
2004 – Migraine and tension headache). 
According to current research results there is an increased expression of PDGF and its 
receptors in malignant human tumors such as ovarian, prostate and NSCLC and also in 
pulmonary hypertension. This proves that PDGF stimulates the angiogenetic process 
both directly and indirectly. PDGF is also involved in the angiogenetic process, in vitro 
and in vivo (Nguewa, Calvo et al. 2011 – Tyrosine kinase inhibitors with 
antiangiogenic). 
1.3.2 Vascular endothelial growth factor 
The vascular endothelial growth factor (VEGF) is a class V receptor tyrosine kinase 
(RTK). The transcription of the VEGF gene is physiologically regulated by hypoxia. 
Alternative splicing and proteolytic processing is involved in the production of different 
isoforms.  
VEGF-A is the most investigative variant and an important mediator of tumor 
angiogenesis, but presently also VEGF-B to VEGF-E are known. These members of the 
VEGF-family occupy the three receptor tyrosine kinases VEGFR-1 (also named Flt-1), 
VEGFR-2 (also named KDR) and VEGFR-3 (also named Flt-4). Flt-1 is expressed on 
endothelial cells and monocytes. Its ligand-binding domain plays an important role in 
early embryogenesis by trapping VEGF-A, with the result that there is a lack of proteins 
for binding on other VEGF-Receptors. Similarly, an absence of the whole Flt-1 receptor 
in vitro shows an overgrowth of vessels, because KDR primarily induces proliferation 
and mitogenic activities. The interaction, between these two is necessary for a correctly 
aligned vascularisation. In both the signaling pathway is a ligand-binding induced 
autophosphorylation, followed by coupling to intracellular signal transducers. It is 
expected that there is an interaction between the different intracellular VEGF-receptors. 
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Redundant KDR plays a significant role in the pathological pathway of angiogenesis. 
The phosphorylation initiates several intracellular pathways including Ras and the 
protein kinase C c-Raf-MEK-MAP kinase cascade. VEGFR3 and KDR are involved in 
lymphatic vessel sprouting, probably by inducing the MAPK pathway. 
Previous studies demonstrate an over-expression of VEGFA in most tumors. There is 
also a correlation between tumor microvessel density and growth. Resumed VEGF 
ligands and their receptor tyrosine kinases have developed into an important target for 
cancer therapy, especially because of their variety of action, i.e. apoptosis of pre-
existing vessels and inhibition of new vessel formation (Nguewa, Calvo et al. 2011 – 
Tyrosine kinase inhibitors with antiangiogenic). 
Further important growth factors in the study of tumor development have been 
mentioned. 
The ret-protooncogen (RET) is a transmembrane protein and a member of the RTK 
class XIV. When growth factors bind to these proteins, a cascade of reactions occurs 
within the cell which instruct the cell to carry out a specific function, for example, 
dividing or maturing to perform specialized functions. 
Flt-3 (Fms-like tyrosine kinase-3) belongs to the class III RTK family to which c-Fms, 
c-Kit, and the PDGFR (Platelet Derived Growth Factor Receptor) also belong.  
Flt-3 is a gene encoding a receptor tyrosine kinase that in this instance time regulates 
hematopoiesis. The receptor is finally activated by an fms-related tyrosine kinase 3 
ligand. The activated receptor kinase subsequently phosphorylates and activates 
multiple cytoplasmic effector molecules in pathways involved in the apoptosis, 
proliferation, and differentiation of hematopoetic cells in bone marrow, such as 
RAS/RAF/MAPK cascades. 
CKIT is a protein on the surface of cells that binds to stem cell factor. Thus it is also 
called stem cell factor receptor. The stem cell factor induces certain types of cells to 
grow. 
CSF-1R is also a cell-surface protein encoded by the CSF-1R gene. It is a receptor for a 
cytokine called colony-stimulating factor 1. This is a cytokine which controls the 
differentiation, production and function of macrophages. 
The epidermal growth factor receptor (EGFR) is situated on the cell surface to bind on 
members of the epidermal growth factor family of extracellular protein ligands, which 
belong to RTK class I. The activation of this receptor includes signal transduction 
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pathways that are involved in the regulation of cellular proliferation, differentiation, and 
survival.  
Simply put, the MAPK (mitogen-activated protein kinases) or ERK (extracellular signal 
regulated kinases) pathway is a chain of intracellular proteins whose activation starts 
with binding of a growth factor to a receptor on the surface of the cell. As a result the 
tyrosine kinase gets activated; that is, the cytoplasmic domain of the receptor gets 
phosphorylated. Subsequently a variety of proteins with a typical SH2 domain can bind 
to the phosphotyrosine residues of the activated receptor. With the help of another 
group of proteins (Guanine nucleotide exchange factors, GEFs), RAS gets activated by 
releasing GDP and gaining GTP. After that the kinase cascade continues contributing 
the serine/threonine-selective protein kinases RAF, MEK and MAPK. At the end of 
these cascades the activated MAP-kinases accumulate in the cell nucleus and start the 
phosphorylisation of several transcription factors. As a result of this the transcription 
and translation of mRNA into protein is possible. Such proteins are needed by a cell, for 
example, to regulate embryogenesis, apoptosis, cell growth and differentiation 
(Wilhelm, Adnane et al. 2008 – Preclinical overview of sorafenib). 
 
1.4 Multikinase inhibitors 
1.4.1 Sunitinib 
Developed by Pfizer sunitinib emerged as a efficacious target to inhibit cell 
proliferation and migration by modify signaling pathways as outlined above mentioned. 
This drug targets different growth factor receptors such as VEGFR-1, PDGFR-alpha, 
PDGFR-beta, FLT3, c-KIT and CSF-1R. Inhibition of those receptors prevents the 
generation of signals that result in tumor growth, angiogenesis and metastasis. There are 
experimental studies which show the antitumor activity effect and implicate the 
reduction of angiogenesis in different xenograft models, such as colon, lung and kidney. 
Presently, sunitinib is a possible first-line treatment of patients with advanced or 
metastatic renal cell carcinoma and gastrointestinal stroma tumor (GIST). It is also 
being investigated as a possible therapy for other cancers, including breast cancer, 
colorectal cancer, and non-small cell lung cancer. Sunitinib even functions as a receptor 
tyrosine kinase inhibitor. In summary there are several studies that conduct research into 
the efficacy of sunitinib, both on its own and combined with other drugs, in the 
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treatment of human tumors (Wilhelm, Adnane et al. 2008 – Preclinical overview of 
sorafenib, Gridelli, Maione et al. 2007 – Sorafenib and sunitinib,). 
1.4.2 Sorafenib 
The oral multikinase inhibitor sorafenib is currently used for the treatment of patients 
with advanced renal cell carcinoma and for patients with unresectable hepatocellular 
carcinoma. Additionally this target is explored in several preclinical cancer models, 
including human colon, ovarian, thyroid, breast, pancreatic and non-small-cell lung 
carcinomas. Sorafenib inhibits a variety of receptor tyrosine kinases considered 
responsible for causing tumorangiogenesis and progression, including VEGFR, 
PDGFR, Flt3, RET and cKIT. Also it is a potent inhibitor of the RAF kinase pathway. 
In some xenograft models there was also a reduction in tumor angiogenesis. On the 
whole it is speculted that sorafinib may inhibit tumor growth by a dual mechanism: it 
affects the tumor angiogenesis directly by inhibiting RAF and KIT signalling, and it 
affects the tumor angiogenesis indirectly by inhibiting the signalling of VEGFR and 
PDGFR (Wilhelm, Adnane et al. 2008 – Preclinical overview of sorafenib, Gridelli, 
Maione et al. 2007 – Sorafenib and sunitinib). 
Sorafenib has been approved for the treatment of HCC (hepatocelllular carcinoma) 
since 2007. The results of the Phase-III study “Sorafenib HCC Assessment Randomized 
Protocol” (Sharp-Studie) show demonstrably that sorafenib, compared to a placebo, 
increases the survival period of patients with HCC by 44 % (journal onkologie, 
27.09.2007). 
All current therapies have a significant number of side effects. Commonly used 
chemotherapeutic agents have some systemic effects such as hair loss, anaemia, 
infections, diarrhea and constipation; nerve, muscle, skin and nail problems are also 
common. Radiation therapy also causes fatigue and skin problems. These side effects 
severely debilitate the patients. 
It is thus necessary to carry out research on new therapeutic agents and combinations of 
these agents in order to minimize the side effects and get a better outcome and quality 
of living. 
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1.5 Phosphodiesterases 
1.5.1 Cyclic nucleotide signalling 
Another promising advance in tumor therapy is the modulation of the intracellular 
cyclic nucleotides cAMP and cGMP. CAMP is typically produced by hormone 
stimulation of seven-transmembrane G protein-coupled receptors. These receptors 
stimulate membrane-associated adenylyl cyclase to convert ATP into cAMP. Three 
effectors of cAMP are known: protein kinase A (PKA), cAMP-gated ion channels, and 
cAMP-activated exchange factors (EPAC). These effectors are called the core effectors 
in all cells. Inside the cell cAMP is degraded by phosphodiesterases (PDEs) (Savai, 
Pullamsetti et al. 2010 – Targeting cancer with phosphodiesterase inhibitors). 
CGMP is generated from GTP after stimulation of soluble guanylyl cyclase (sGC) by 
nitric oxide (NO) or particulate guanylyl cyclase (pGC) by natriuretic peptides (NP). 
These so-called second messengers can now bind to protein kinase G (PKG) and 
cGMP-gated ion channels or get deactivated by PDEs. PKG catalyses the 
phosphorylation of a number of physiologically relevant proteins involved in the 
contractile activity of smooth muscle cells. 
All effectors of cAMP and cGMP induce cellular responses such as proliferation, 
apoptosis, differentiation, vasodilation or vasoconstriction and inflammation. In breast 
cancer cells and colon cancer cells the increasing intracellular concentrations of cAMP 
may induce apoptosis, arrest growth, and rarefy cell migration (Savai, Pullamsetti et al. 
2010 – Targeting cancer with phosphodiesterase inhibitors). 
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Figure 1: Cyclic nucleotide phosphodiesterase signalling. This graphic shows the basic synthetic, regulatory, 
and downstream pathways that are involved in the effects of endogenous cyclic adenosine monophosphate 
(cAMP) and cyclic guanosin monophosphate (cGMP). Cyclic nucleotide phosphodiesterases (PDEs) catalyze 
the hydrolysis of cAMP and/or cGMP and thereby regulate the amplitude and duration of cell signalling. 
Mechanisms mediated by cAMP and cGMP (Savai, Pullamsetti et al. 2010 – Targeting cancer with 
phosphodiesterase inhibitors). 
1.5.2 Phosphodiesterase family 
Phosphodiesterases are key enzymes modulating the existent amount of the second 
messangers cAMP and cGMP by controlling the degradation. Currently, there are 11 
known families of phosphodiesterases (PDE1- PDE11). They are named and classified 
because of the similarity of their sequences, preference of substrate, and sensitivity to 
various inhibitors. Some of the PDE gene families have isoform subfamilies produced 
in different but according to genes. These so-called subfamilies distinguish themselves 
through their three-dimensional structure, kinetic properties, regulatory mechanisms, 
intracellular localisation, cellular expession and inhibitor sensitivities. The role of PDEs 
is determined according to their family-specific inhibiors (Omori, Kotera 2007 – 
Overview of PDEs and their). Each PDE molecule can be divided into three regions: the 
N-terminal splicing region, a regulation domain, and a C-terminal catalytic domain (Ke, 
Wang 2007 – Crystal structures of phosphodiesterases). Within the PDE families there 
are no big differences concerning the N-terminal splicing region. The conserved 
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catalytic domain contains about 300 amino acids and shows considerable divergence. 
The regulatory domains offer variations of structure, i.e. GAF in PDE2, 5, 6, 10 and 11. 
GAF domains belong to the group of SMBDs (small molecule binding domains). This 
group consists of the first three protein classes in which these domains have been 
discovered. These three are the cGMP-specific phosphodiesterases, the Adenylyl 
cyclase from the cyanobacterium Anabaena and the E.coli transcription factor Fh1A 
(Hofbauer 2007 – Die GAF-Domänen der humanen Phosphodiesterase). In general the 
regulation of PDEs is a complex process involving cellular distribution and intracellular 
compartmentalization (Lugnier 2006 – Cyclic nucleotide phosphodiesterase PDE 
superfamily). 
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Table 1: Classification and expression of phosphodiesterases (PDEs) 
Family Members Substrate Tissue/cellular 
expression 
Commonly used 
inhibitors 
PDE1 A,B,C cAMP/cGMP 
Lung, heart, brain, testes, 
sperm, smooth muscle, 
lymphocytes, macrophages 
Vinpocetine, IC224, 
SCH51866, 8-MeoM-
IBMX 
PDE2 A cAMP/cGMP 
Lung, liver, heart, brain, 
macrophages, endothelial 
cells, adrenal gland 
EHNA, BAY60-7550, 
PDP, IC933 
PDE3 A,B cAMP/cGMP 
Lung, heart, kidney, liver 
immune cells, dipocytes, 
hepatocytes, platelets 
Milrinone, 
Tolafentrine, 
Cilostazol, 
Cilostamide, 
Trequinsin, OPC-
33540, 
Dihydropyridazinone, 
Lixazinone 
PDE4 A,B,C,D cAMP Ubiquitous 
Cilomilast, Rolipram, 
Ro20-1724, 
Roflumilast, 
AWD12281, 
V11294A, SCH35159, 
Denbufylline, 
Arofylline 
PDE5 A cGMP 
Lung, brain, heart, kidney, 
skeletal muscle, platelets 
Sildenafil, Tadalafil, 
DA8159, E402, 
Vardenafil, Zaprinast, 
DMPPO, 
Dipyridamole 
PDE6 A,B,C,D,G cGMP Photoreceptors Zaprinast 
PDE7 A,B cAMP 
Heart, liver, brain, kidney, 
pancreas, testes, skeletal 
muscle, immune cells 
BRL 50481, IC242, 
Dipyridamole, BMS-
586353, Thiadiazoles 
PDE8 A,B cAMP 
Liver, heart, kidney, brain, 
spleen, ovary, testes, 
colon, thyroid, skeletal 
muscle, immune cells 
Dipyridamole 
PDE9 A cGMP 
Lung, liver, brain, spleen, 
kidney, prostate 
BAY73-669, 
SCH51866, Zaprinast 
PDE10 A cAMP/cGMP Heart, brain, thyroid, testes 
Papaverine, 
Dipyridamole, PQ-10 
PDE11 A cAMP/cGMP 
Liver, kidney, thyroid, 
testes, prostate, pituitary 
glands, skeletal muscle 
Dipyridamole 
 
1.5.3 Inhibitors 
In general PDE family-specific inhibitors make it possible to get insights into the 
functional role of specific PDEs and may be useful for predicting the potential 
therapeutic effects of targeting. 
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Inhibitors of PDEs can be classified into nonselective phoshodiesterase inhibitors and 
selective inhibitors. Methylated xanthines and their derivatives belong to the group of 
nonselectives. The first inhibitor methylxanthine was described in the literature in 1962 
(Butcher, Sutherland 1962 – Adenosine 3',5'-phosphate in biological materials). The 
selective PDE inhibitors are currently being investigated for the treatment of a variety of 
diseases, as these examplesillustrate. 
The PDE2 inhibitor may be of therapeutic interest in pneumococcal pneumonia 
(Witzenrath, Gutbier et al. 2009 – Phosphodiesterase 2 inhibition diminished acute). 
The PDE3 inhibitor Milrinone is presently used in the acute treatment of heart failure to 
diminish long-term risk (Shin, Brandimarte et al. 2007 – Review of current and 
investigational). The PDE4 inhibitors like roflumilast are generally accepted in the 
treatment of asthma (Hoymann, Wollin et al. 2009 – Effects of the phosphodiesterase 
type, Böhmer, Nassr et al. 2009 – The targeted oral) and COPD (Gross, Giembycz et al. 
2010 – Treatment of chronic obstructive pulmonary). Research is being conducted in 
the development of the PDE7 inhibitor ASB16165 and may be useful for the treatment 
of diseases in which cytotoxic T lymphocyte has a pathogenic role, e.g. autoimmune 
diseases (Kadoshima-Yamaoka, Murakawa et al. 2009 – Effect of phosphodiesterase 7 
inhibitor). Specific inhibitors for PDE8-PDE11 have been detected recently and their 
design has already begun. 
1.5.4 Phosphodiesterase 5 and the specific inhibitor sildenafil 
Phoshphodiesterase 5 isozymes were found in several tissue types including lung, brain, 
heart, kidney, skeletal muscle and platelets. This enzyme causes a decrease of cGMP 
inside a cell. Consequently a specific PDE5 inhibitor like sildenafil is responsible for an 
increasing cGMP concentration. Sildenafil was the first orally active, effective therapy 
for the treatment of erectile dysfunction. The mechanism of action in penile erection is 
described below: 
Nitric Oxide, NO, binds to the receptors of the enzyme guanylate cyclase, which results 
in increased levels of cyclic guanosine monophosphate (cGMP). This leads to smooth 
muscle relaxation (vasodilation) of the intimal cushions of the helicine arteries, 
resulting in increased inflow of blood and an erection. The drug now arrests the 
degradation of cGMP and prolongs the duration of an erection. However the drug was 
originally studied for its treatment of hypertension and angina pectoris. 
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It was discovered that whilst the drug efficacy in treating against angina pectoris was 
insignificant, it was quite effective in causing erections. In the year 1996 the 
pharmacological company called Pfizer decided to market it for the treatment of erectile 
dysfunction. 
Sildenafil is also used for the treatment of pulmonary hypertension, which it relieves by 
inducing vasodilatation. Pulmonary hypertension is an increase in blood pressure in 
lung vasculature, including pulmonary arteries, pulmonary veines and pulmonary 
capillaries. 
In general the regulation of PDEs in several cancers and the antitumor effect of PDE 
inhibition is currently investigated and discussed. The overexpression of PDE5 appears 
in many carcinomas, including adenocarcinomas. These phosphodiesterases are 
supposed to play a role in the development of carcinogenesis. Data demonstrate 
differences in PDE and cyclic nucleotide levels between neoplastic and normal tissues, 
especially in those with increased cGMP PDE activity (Savai, Pullamsetti et al. 2010 – 
Targeting cancer with phosphodiesterase inhibitors). 
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2 Aims of the study 
 Expression profile of tyrosine kinase receptor in A549 tumor tissue, human 
donor monocytes, macrophages, lymphocytes and fibroblasts 
 In vivo effects of PDE5 inhibitor sildenafil in combination with multikinase 
inhibitor sunitinib or sorafenib in sn adenocarcinoma mouse model 
 Analysis of morphology, angiogenesis and proliferation in tumor tissue 
 Analysis of the role of angiogenesis in tumor tissue growth 
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3 Material 
3.1 Cell culture 
A549 cells 
A549 cells serve as a model to draw inferences about adenocarcinomic cells as a 
subgroup of NSCLC. The cell lines were obtained from American Type Culture 
Collection (ATCC). 
A549 medium 
A549 cells were grown in DMEM plus 10% FCS, 1% penicillin-streptomycin, 1% 
vitamines, 1% glutamin, 1% non-essential aminoacid. 
1% trypsin/PBS 
Freezing medium 
RPMI-1640 70%, FCS (filtered) 20%, DMSO 10% 
 
3.2 Immunohistochemistry 
PBS 10x buffer 
NaCl 80.0 g, KCl 2.0 g, Na2HPO4x2H2O 11.5 g, KH2PO4 2.0 g 
dissolve in 900 ml aqua dest. and then fill up to 1 L. 
For using mix one part 10x buffer with 10 parts aqua dest. for getting 1x buffer 
concentration. 
For staining 10% BSA in PBS plus 0.013% NaN3 
Recipes for Goldner - Masson - Staining 
Ponceau acid fuchsin solution 
Ponceau de Xylidine 0.2 g, Acid fuchsin 0.1 g, Acetic acid 1%  0.6ml 
aqua dest. 300 ml 
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Orange G - Solution 
Phosphorwolframacid 8 g, Orange G 4 g, aqua dest. 200 ml 
Light green - Solution 
Light green SF 0.4 g, acetic acid 1% 0.4 ml, aqua dest. 200 ml 
3.3 Reagents 
Table 2: Reagents for immunohistochemistry and PCR 
Product name Company 
immunohistolochemistry  
Acetic acid, Rotipuran 100% Roth, Germany 
Albumin bovine fraction V Serva, Germany 
Citrate buffer pH 6, 20x concentration Zytomed, Germany 
Eosin-y-alcoholic Thermo Fisher Scientific, UK 
Ethanol 70 %, denatured with 
Methylethylketon 
Fischar, Germany 
Ethanol 96 %, denatured with 
Methylethylketon 
Fischar, Germany 
Ethanol 99.6%, denatured with 
Methylethylketon 
Fischar, Germany 
Fe-Hematoxylin A-solution Weigert Chroma, Germany 
Fe-Hematoxylin B-solution Weigert Chroma, Germany 
Fetal calf serum (FCS) Invitrogen Gibco, Germany 
H2O2, puriss. p.a. 30% Merck, Germany 
Hämalaun solution, acid Chroma, Germany 
Hematoxylin ready to use Invitrogen, Germany 
Hydrogen Peroxide 30% Merck, Germany 
ImmPRESS kit anti-rabbit Ig, peroxidase Vector Laboratories, USA 
Isopropylalkohol (2-Propanol) Sigma-Aldrich, Germany 
Light green Sigma-Aldrich, Germany 
Methanol, reinst, p.a. Riedel-de-Häen, Germany 
NovaRED substrate kit for peroxidase Vector Laboratories, USA 
Orange G Chroma, Germany 
Pertex Medite, Germany 
Ponceau de Xylidine Chroma, Germany 
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Potassium dihydrogen phosphate Merck, Germany 
Potassium chloride Roth, Germany 
Proteinase K Dako, USA 
Sodium chloride Roth, Germany 
Sodium hydrogen phosphate dihydrate Merck, Germany 
Trypsin, Digest All 2 Zytomed, Germany 
Wolframphosphoracid Hydrat, p.a. Merck, Germany 
Xylol Roth, Germany 
Zymed Digest-All Trypsin Kit Zytomed, Germany 
PCR  
ImProm-II
TM 
Reverse Transcriptase Promega, Germany 
Magnesium Promega, Germany 
Oligo(dT15) Primer Promega, Germany 
PCR Nucleotide Mix Promega, Germany 
SYBER® Green PCR Kit Qiagen, Germany 
 
3.4 Antibodies 
3.4.1 Immunohistochemistry 
Table 3:Antibodies 
Product name Company Dilution 
Alpha-actin Sigma 1:900 
C-Kit (C-19): sc-168 Santa Cruz Biotechnology 1:1500 
EGFR Abcam 1:500 
Flt-1 / VEGFR1 Ab-1 Thermo Scientific 1:1 
PCNA Santa Cruz 1:100 
PDE5a Scottish Biometrics 1:50 
PDGFR, alpha Thermo Scientific 1:50 
PDGFR, beta Ab-1 Thermo Scientific 1:100 
vWF Dako 1:600 
 
 
 
20 
 
3.5 Primer 
Table 4: PCR primer 
Gene (human) Accession 
Primer sequence 
forward 
Primer sequence 
reverse 
colony stimulating 
factor 1 receptor 
(CSF-1R)  
NM_005211  
5'-GTG GCT GTG 
AAG ATG CTG 
AA-3'  
5'-CCT TCC TTC GCA 
GAA AGT TG-3'  
epidermal growth 
factor receptor 
(EGFR)  
NM_005228  
5'-CTC AGC CAC 
CCA TAT GTA CC-
3'  
5'-CGT CCA TGT CTT 
CTT CAT CC-3'  
Fms-related tyrosine 
kinase 1 (FLT-1)  
NM_002019  
5'-TCG TGT AAG 
GAG TGG ACC 
AT-3'  
5'-CGA GTA GCC 
ACG AGT CAA AT-3'  
Fms-related tyrosine 
kinase 3 (FLT-3)  
NM_004119  
5'-AGA GCA CGT 
GTG CTT TTA CC-
3'  
5'-TAC TTC TGA CTG 
GCC CTG AG-3'  
Fms-related tyrosine 
kinase 4 (VEGFR3, 
FLT4)  
NM_002020  
5'-GGT TAA GGC 
ATA CGA GAG 
CA-3'  
5'-TCT GTG TTG CCA 
GCG TAT AA-3'  
kinase insert domain 
receptor (KDR)  
NM_002253  
5'-GTT CTT GGC 
TGT GCA AAA 
GT-3'  
5'-GTC TTC AGT TCC 
CCT CCA TT-3'  
phosphodiesterase 2A, 
cGMP-stimulated 
(PDE2A)  
NM_002599  
5'-CCT ATA TCC 
CTG AGC TGC 
AA-3'  
5'-GGA AGT CCA 
GCG AGT TGT TA-3'  
phosphodiesterase 5A, 
cGMP-specific 
(PDE5A)  
NM_033437  
5'-AAG CAA ATG 
GTC ACA TTG GA-
3'  
5'-TCT GGA AGT TCT 
GCA CAA GG-3'  
platelet-derived 
growth factor receptor, 
alpha polypeptide 
(PDGFRalpha)  
NM_006206  
5'-CCA GCA GTT 
TCC AGT CCT AA-
3'  
5'-ACA GAT TGG 
CAG ACC ACA TT-3'  
platelet-derived 
growth factor receptor, 
beta polypeptide 
(PDGFRbeta) 
NM_002609  
5'-CCC AGC AAG 
TCT CAA GAA 
CA-3'  
5'-GGT GAT CTC ATT 
TGC CCT CT-3'  
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ret proto-oncogene 
(RET)  
NM_020630  
5'-TGT CCT CTT 
CTC CTT CAT CG-
3'  
5'- AAT TCC CAC 
TTT GGA TCC TC-3'  
V-kit Hardy-
Zuckerman 4 feline 
sarcoma viral 
oncogene homolog 
(KIT)  (c-KIT)  
NM_000222  
5'-CCG TGG TAG 
ACC ATT CTG TG-
3'  
5'-GTG CCC ACT ATC 
CTG GAG TT-3'  
 
3.6 Equipment Table 
Table 5: Equipment 
Bench Hera safe HS18 Heraeus Instruments, Germany 
Centrifuge 3 S-R Heraeus Instruments, Germany 
Combi-Tips Eppendorf, Germany 
Culture dishes BD Falcon, Germany 
Incubator Function line BB16 Heraeus Instruments, Germany 
Incubator histology Memmert, Germany 
Microscope Leica, Germany 
Light Microscope in Cell Culture, DM IL Leica, Germany 
Multipette plus Eppendorf, Germany 
Pipette 10 ml, 25 ml, 50 ml BD Falcon, Germany 
Pipette P20, P100, P200, P1000 Eppendorf, Germany 
Pipette peaks  Sarstedt, Germany 
Pipette peaks PCR Sorenson, USA 
Vortex REAX control Heidolph, Germany 
Waterbath GFL 1083 Gesellschaft für Labortechnik, Germany 
Centrifuge in Cellculture  Thermo Fisher Scientific, UK 
Cell Scraper, BD Falcon 18 cm BD Biosciences, USA 
Falcon Tubes 50 ml, 15 ml  Greiner Bio-One, Germany 
Freezer +4 ˚C  Bosch, Germany 
Freezer -20 ˚C  Bosch, Germany 
Frezer -80 ˚C  Thermo Fisher Scientific, UK 
Freezing Box for Cryotubes  Sarstedt, Germany 
PCR Plates, ABgene Thermo-Fast  Thermo Fisher Scientific, UK  
T3000 Thermocycler Biometra, Germany 
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pH-Meter HISTO Knick, Germany 
qPCR Device, Mx3000P  Stratagene, USA  
Tubes 1,0 ml; 1,5 ml; 2 ml  Eppendorf, Germany  
 
4 Methods 
4.1 Animals 
Immunodeficient balb/c nude male mice aged 7 - 8 weeks were acquired from Charles 
River, kept under specific pathogen-free conditions in an animal house with free access 
to food and water. 
Animals were handled in accordance with the European Community recommendations 
for experimentation. RP Darmstadt No: V54-19c20/15-B2/290 
4.1.1 Anaesthesia for subcutaneous infiltration 
For the subcutaneous infiltration of A549 cells into the right backside of the mice the 
following composition was used in a ratio of 1:1:2. 
Ketavet 100 mg : Rompun 2% : NaCl 0.9% 
Per mice 40 - 100 µl of anaesthesia-mix was given. 
4.1.2 Tumor growth in nude mice 
Tumor genesis was induced by subcutaneous injection of A549 cells (2.5 x 106 
cells/200 µl PBS) in 7 - 8 week-old balb/c nude male mice. The size of the tumor was 
measured using digital calipers (Mitutoyo., UK). The tumor volume (TV) was 
calculated by the formula: TV (mm³) = (L x W²)/2. L means the longest dimension of 
the tumor (in mm), and W is the shortest dimension of the tumor (in mm). Every day 
each mouse got the treatment with the specific group therapy, every fourth day of a total 
24 days of therapy, the tumor growth was measured. After 24 days of measuring the 
mice were sacrificed and tumors were prepared. 
4.1.3 Treatment groups 
There were seven groups: control group (n = 10) no treatment; placebo group (n = 7)  
treated with methylcellulose; sildenafil group (n = 7) treated with 100 mg/kg bw; sutent 
group (n = 7) treated with 40 mg/kg bw; sildenafil + sutent group (n = 7) treated with 
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100 mg/kg bw + 40 mg/kg bw; sorafenib group (n =7) treated with 50 mg/kg bw; 
sildenafil + sorafenib group (n = 7) treated with 100 mg/kg bw. 
 
4.2 Cell culture 
A549 cells were grown in a prepared A549 medium at 37 °C, 5% CO2 in humid 
atmosphere. 
For further processing the cells were cultivated in 100 mm dishes. 
All liquid materials had to be warmed up in the warm water bath to 37 °C excepting the 
freezing medium. Which had to be 0 °C when used. This temperature was reached by 
laying the tube with the freezing medium on crushed ice. 
Trypsinization and splitting 
After sucking off the supernatant 6 ml of trypsin were admitted to the adherent cells. 
The dish was put back into incubator for 1-3 minutes to detach the cells. 
During that time a 50 ml tube was prepared with 2 ml of FCS and after that the cells 
were put in by using a pipette. The dish was spoiled with 10 ml of standard medium and 
the solution was although poured in. 
Subsequently the tube was centrifuged at 1600 rpm for 8 minutes. 
The supernatant was disposed and the cell clot was resuspended with 6 ml A549 
medium and put back to 2-4 new dishes which had been before been prepared with 7ml 
medium. Splitting mostly 1:3 or 1:4 when the cells were 80% - 90 % confluency before. 
Freezing of cells 
The cell clot from one dish resulting from centrifugation was mixed with 900 µl of 
freezing medium. Then resuspended and put into freezing tubes 450 µl of each. 
Next the tubes were kept for 24 hours in -80 °C before being froan at -130 °C. 
All patients whose tissue was used in this study gave their written informed consent. 
 
4.3 RNA isolation 
RNA was isolated from cells and tissue using TRIzolTM reagent. For the isolation of 
RNA from cultured cells, the culture medium was removed and cells were washed with 
PBS, than resuspended in TRIzol. TRIzol-cell-mix was collected and transferred to a 
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1.5 ml tube using cell scraper and pipette. In order to get RNA from tumor or lung 
tissue 30 mg of tissue were crushed with 700 µl of TRIzol on ice. Samples were 
incubated at room temperature (r.t.) for 10 min. After that 200 µl of chloroform were 
added then centrifuged at 12000 rpm, 4 ºC for 15 min. The aqueous phase was 
transferred to a new tube, mixed with 500 µl of isopropanol (per ml TRIzol) inverted 
and incubated at r. t. for 10 min. Samples were centrifuged for 10 min at 12000 rpm at 4 
°C. The supernatant was discurded. Then the pellet was washed with 1 ml 75% EtOH 
and centrifuged at 7500 rpm at 4 °C. The RNA pellet was finally redissolved in 10-30 
µl of DEPC-treated water for 10 min at 55 ºC. Samples were placed on ice and 
quantified by NanoDrop device. Samples were stored at -80 ºC immediately after RNA 
isolation. 
 
4.4 cDNA synthesis 
The RNA isolated in this way was then used to synthesize complementary DNA 
(cDNA) using the ImProm II reverse transcription system. 1 µl of RNA and 1 µl of 
oligo(dt) primer were filled to a final volume of 5 µl with nuclease-free water in order 
to equalize the RNA concentration. 
Tubes were placed into the thermocycler and denatured at 70 °C for 6 min and then 
cooled at 4 °C for 5 min. The second step involved DNA synthesis itself, the reverse 
transcription reaction mix (1 µl of RT, 1 µl of dNTP-Mix [10 mM], 4 µl of reaction 
buffer, 2 µl of MgCl2 [25 mM], 0.5 µl of ribonuclease inhibitor [40 U/µl] and 6.5 µl of 
DEPC-treated water) was added. Again tubes were placed into the thermocycler now 
programmed as follows: 25 °C for 5 min, 42 °C for 60 min, followed by 70 °C for 15 
min to inactivate the RT.  Directly after synthesis cDNA was frozen immediately and 
stored at -20 °C. 
 
4.5 Quantitative real time polymerase chain reaction 
Quantitative real time polymerase chain reaction (qPCR) is a method based on the 
principles of PCR allowing not only to amplify specific DNA sequences but also to get 
information about their quantity by measurement of fluorescence dye attachment to the 
product during amplification. The amplification is performed by repetition of the three 
key steps of PCR: denaturation, primer annealing and elongation. 
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The qPCR was performed in Mx3000P® device from Stratagene, the reaction mix was 
prepared with Platinum® SYBR® Green qPCR SuperMix-UDG. 25 µl of the reaction 
mix includes 12,5 µl Platinum® Syber® Green qPCR SuperMix-UDG (end conc. 1x), 1 
µl MgCl2 50 mM (end conc. 5 mM (3 mM issued in SuperMix)), 0.5 µl forward [10 
mM] and 0.5 µl backward [10 mM] primer (end conc. 0.2 µM each), ROX Reference 
Dye [25 µM] (end conc. 0.1 µM), 2 µl cDNA [0.25 µg/µl] (end conc. 0.5 µg) and 8.4 µl 
DEPC-treated water as components. Then the RT-PCR machine was programmed as 
follows: activation 95 °C for 10 min, 40 cycles with denaturation at 95 °C, annealing 58 
°C, extension 72 °C each 30 s, denaturation 95 °C for 1 min. For the negative control, 
the cDNA was omitted. 
The relative transcript rate of the genes of interest was compared to the same samples 
rate of the house keeping gene HRPT presented as ∆Ct values (∆Ct = Ctreference – 
Cttarget); Ct standing for cycle threshold, representing the point where fluorescence 
exceeds background. 
 
4.6 Immunohistochemistry 
4.6.1 Staining methods 
For both methods (protein kinase K and trypsin) the slides had to be prepared in the 
same way. They were stored over night at 37 °C and before starting at 59 °C for 60 min. 
Then they were immersed in series into the following solutions: 3 times in xylene for 10 
min, 2 times in  absolute 99.6%  ethanol  for 5 min, 96% ethanol  for 5 min, 70% 
ethanol  for 5 min. 
For using protein kinase K the slides had to be cooked in citrate buffer pH 6 for 20 min, 
kept warm in buffer for 10 min, then 30 min at r. t., cleaned with aqua dest. 2 times for 
5 min. 
Next steps for both methods: 100 ml of methanol plus 100 ml 30% H2O2  for 20 min, 
aqua dest. for 5 min, 2 times in PBS for 5 min. 
According to the manufacturer‟s instruction each slide was threated with either protein 
kinase K and stored at r.t. or trypsin and stored at 37 °C for 15 min, washed in aqua 
dest., 2 times in PBS for 5 min followed by 180 µl of 10% BSA  and stored 60 min at 
r.t. Subsequent to this the slides were washed again two times with PBS for 5 min and 
ongoing 2.5% normal horse serum were put drop by drop on the slides for 20 min. After 
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removing the supernatant, slides were incubated with primary antibody over night at 4 
°C. 
The next day, slides were spoiled for 2 h in PBS, buffer change every 15 min. Then 
secondary-antibody was put on each slide, after which slides were stored for 30 min at 
r.t., then PBS 4 times for 5 min. Subsequently the NovaRED – substrate (5 ml aqua dest 
+ 3 drops Reag. 1, mix, plus 2 drops Reag.2, mix, plus 2 drops Reag.3, mix, plus 2 
drops Hydrogen Peroxide, mix) was put on the slides while developing under the 
microscope for sec. to 15 min according to the antibody. Following the final alcohol 
line: 96% ethanol  for twice 2 min, isopropanol for twice 5 min, xylene for three times 5 
min. Last step covering with pertex and glass. 
For HE-staining the slides were dehydrated, put into aqua dest. for 2 min, followed by 
20 min of incubation in haematoxylin solution (mayer), 5 min tap water, 1 min 96% 
Ethanol, 4 min eosin-y-alcoholic and washing in aqua dest. Followed by the final 
alcohol line as decribed before. 
For trichrome staining the first steps were the same. After 5 min in 70% ethanol the 
slides were put directly in Fe hematoxylin Weigert A und B (1:1) for 10 min followed 
by 5min blueing under tap water and put into ponceau-acid fuchsin for 10 min. Then 4-
5 times dip in 1% acetic acid till no more streaks of colour were visible and stayed in 
orange g-solution for 5 min before washing with 1 % acetic acid again. Finally the 
slides had to stay in lightgreen for 20 min until the alcoholic line started. 
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4.7 Quantification 
 
 Figure 2: Quantification by Leica Qwin, Example picture 
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Figure 2 shows an example for quantification. The upper image shows a histological 
slide of a tumor  after  staining  procedure. Cells were marked blue, in this case specific 
PDE5 receptors were marked red. Due to the staining procedures tumor stroma also got 
colored red. To distinguish between the PDE5 receptors and the tumor stroma Leica 
Microsystems have developed a quantification program called Leica QWin.This 
program just marked the specific red color before selected on the whole slide. The same 
procedure followed for the blue stained areas. At the end the tumor slide was scanned, 
and the percentage of color was put in relation to the tumor size and to the two colors as 
illustrated in the screenshot below. 
 
Figure 3: Dualstanding Analyse, Screenshot example 
 
4.8 Statistics 
All data are given as the mean +/- SEM. Graphical and statistical analyses were 
performed using commercial computer software (GraphPad Prism 5, San Diego, CA, 
USA). Statistical significance of differences between two groups was established as p < 
0,05 using the unpaired t test with Welchs correction. 
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5 Results 
5.1 Profiling of receptor expression 
By RT-PCR the expression profile of the following TKR were verified in control A549 
cells, in A549 tumor tissue, in human fibroblasts, monocytes, macrophages, 
lymphocytes and in human donor lung tissue (figure 4 A-L). 
The mRNA expression levels were normalized to housekeeping gene (HRPT). CKIT, 
PDE5a, RET, CSF-1R, Flt3, PDGFR-alpha and PDGFR-beta, EGFR and VEGFR3 
were expressed in all kinds of used tissues. Flt1 and KDR were expressed in A549 
tumor tissue, in human fibroblasts, monocytes, macrophages, lymphocytes and human 
donor lung tissue, but not in A549 cells. The results show that in figure 4 all genes were 
differently expressed. We do not have an exact control cell to make a fold change. 
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Figure 4: mRNA expression of tyrosine kinase receptors in A549 tumor cells, A549 tumor tissue, in human 
fibroblasts, monocytes, macrophages, lymphocytes and in human lung donor tissue. Expression of the cytokine 
receptor cKIT(A), the vascular endothelial growth factor Flt-1 (B), the cGMP-specific phosphodiesterase type-
5A (C), the proto-oncogene RET (D) the colony stimulating factor 1 receptor CSF-1R (E), the receptor 
tyrosine kinase Flt3 (F), the platelet-derived growth factor receptor alpha (G) and beta (H), the epidermal 
growth factor receptor EGFR (I), the vascular endothelial growth factor KDR (K) as well as the vascular 
endothelial growth factor receptor 3 VEGFR3 (L) was analysed by real-time quantitative PCR using the ∆Ct 
method, that is by comparing the Ct values of the samples with the control gene HRPT. 
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5.2 Tumor growth 
No significant differences were observed comparing control and placebo groups to 
treated groups at day 4 and 8 after A549 cell injection. In the third measurement (day 
12), both the control and the placebo group showed on average, an increased volume of 
tumor – twice the volume compared to the sunitinib + sildenafil group – while the other 
groups hardly showed any changes from the previous measurements. The fourth 
measurement (day 16) also demonstrated a significantly larger volume in the control 
and placebo groups than the other groups. There were also clear differences between the 
mono-therapy sildenafil compared to the mono-therapy groups sorafenib and sunitinib 
as well as the combined therapy groups sunitinib + sildenafil and sorafenib + sildenafil. 
The last four groups showed on average half the tumor volume of the first two mono-
therapy group sildenafil; the control and placebo group showed, on average, triple the 
tumor volume. 
Taking everything into consideration, the combined therapy of sunitinib + sildenafil 
showed, for the duration of the experiment and in comparison to the first measurement 
on day 4, no increase in volume of the tumor; that is, no increase in tumour growth. 
On the days when the measurements were carried out, the groups sorafenib + sildenafil, 
sunitinib and sorafenib showed similar volumetric ratios with no significant differences. 
 
Figure 5: Subcutaneous tumor size over the course of time A549 cells were injected subcutaneously into balb/c 
nude male mice. There were seven groups: Control group (without treatment), placebo group (with 
methylcellulose), sildenafil (100 mg/kg bw), sutent (40 mg/kg bw) and sorafenib (50 mg/kg bw), sutent + 
sildenafil (combination of 40 mg/kg bw sutent and 100 mg/kg bw sildenafil, daily) and sorafenib + sildenafil 
(combination of 50 mg/kg bw sorafenib and 100 mg/kg bw sildenafil, daily) Tumor size was measured over 28 
days by digital calipers in a time-dependent manner (every fourth day) 
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Figure 6: HE (1) and trichrome (2) stainings of original scanned slides of A549 tumor tissue 
 
 
 A) H&E staining B) Trichrome 
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Figure 6 shows the original proportions of the tumor volumes at day 28 after the 
injection of A549 tumor cells in relation to figure 5. Haematoxylin-eosin staining (HE) 
uses haematoxylin solution for staining of the nucleus (nucleus stains blue/ dark violet) 
and eosin solution for cytoplasmic staining (cytoplasm, collagen stain red). Masson 
trichrome staining is a classical staining method for fibrose tissue with the result that 
nuclei stain black, cytoplasm, muscle, erythrocytes stain red, and collagen stains blue. 
The intensity is not matter to compare the different sizes. Control and placebo group 
shows the biggest increase almost equal. The sildenafil group is bigger than the other 
monotherapie groups and combination therapie groups but taller than control and 
placebo. Sunitinib, sorafenib and sutent are almost equal in size, too. These three groups 
totally are smaller than placebo, control and sildenafil groups but still bigger than 
sildenafil + sutent group. In the trichrome staining it appears that both combination 
groups and sorafenib monogroup have a higher content of collagen compared to the 
other groups.  
  
 
 
 
 
 
 
 
5.3 Tyrosine kinase receptor expression 
Figure 8 shows the statistical analysis of the immunohistochemical quantification of the 
examined tyrosine kinase receptors (A - F). 
In general, there was a high density of all tyrosine kinase receptors in both the placebo 
and the control group. Flt-1 shows significantly reduced values for the mono-therapy 
groups (sildenafil, sunitinib, sorafenib) and the combined therapy groups (sildenafil + 
sunitinib and sorafenib + sildenafil). For EGFR there was scarely any expression under 
Figure 7: This picture shows an enlarged example of HE (left) and trichrome (right) staining 
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therapies with sutent and sorafenib, sorafenib + sildenafil and sutent + sildenafil 
appeared. As a mono-therapy, sildenafil showed a significantly higher density of 
receptors for EGFR, but compared to the two control groups (control and placebo), this 
was significantly lower. The expression of PDE5 subsided for the therapy with 
sildenafil and sorafenib + sildenafil; surprisingly, there was no significant reduction 
with the combination sildenafil + sunitinib. The two other mono-therapy groups also 
showed minimal influence on the PDE5 receptor expression. 
The combined groups and sildenafil showed a stronger expression of PDGFR-alpha 
than the groups sunitinib and sildenafil. There was almost no expression for PDGFR-
beta for the combined therapies and for the sorafenib therapy on its own. Nevertheless, 
sildenafil and sunitinib showed significantly fewer expressions compared to the control 
and placebo groups. There was no overall significant reduction in the tyrosine kinase 
receptor cKIT; however, the expression did decrease under the inhibition therapy. The 
smallest manifestation became apparent under the combined therapy of sunitinib + 
sildenafil. Overall the statistical evaluation confirms the optical impressions of the 
stainings seen in fig. 12 
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Figure 8: Immunohistochemical quantification of expression of tyrosine kinases receptors in A549 tumor 
tissue in control group and after 28 days of oral inhibitors administration with methylcellulose (placebo), 
sunitinib, sildenafil, sorafenib, sunitinib + sildenafil, sorafenib + sildenafil. *P<0.5, **P<0.001, ***P<0.001 vs 
placebo group. n = 7-10. 
 
 
 
   
 
 
 
  
Figure 10: Immunohistochemical quantification of active cell divisions and expression of vWF +  alpha actin 
receptor. 10 A shows a drastic decrease of active cell divisions in all therapeutic groups, compared to controls. 
In figure 10 B the amount of blood vessels is shown. The mono-therapy groups showed a decline of 
vascularization, the combination therapies rather showed an increase of vascularization. Of particular interest 
is the observation that for the therapy with sorafenib + sildenafil, there was just as high a density of blood 
vessels as was in the control groups in A549 tumor tissue in control group and after 28 days of oral inhibitors 
administration with methylcellulose (placebo), sunitinib, sildenafil, sorafenib, sunitinib + sildenafil, sorafenib + 
sildenafil. *P<0.5, **P<0.001, ***P<0.001 vs placebo group. PCNA (A), vWF+alpha actin (B). n = 3 
cKIT Flt-1 
PDE5 PDGFRalpha
EGFR 
PDGFRbeta 
Figure 9: This picture shows a representative magnification of fig. 12. The arrows demonstrate the 
specific antibody staining. 
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Figure 11: Representative pictures of immunohistochemical staining used for figure 10. vWF+alpha actin 
staining. The arrows exemplary denote the stained vessels. PCNA staining. The arrows exemplary denote the 
active cell devision. Vessel and active cell devision were counted under mikroskope. 
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Figure 12: Representative pictures of immunohistochemical staining that were used for the quantitative 
analysis (figure 7). (Generic magnification see figure 2.) Expression of tyrosine kinase receptors in A549 tumor 
tissue in control group and after 28 days of oral gavage with methylcellulose (placebo), sunitinib, sildenafil, 
sorafenib, sunitinib + sildenafil, sorafenib + sildenafil, cKIT (1), Flt1 (2), EGFR (3), PDE5 (4), PDGFR-alpha 
(5) and PDGFR-beta (6).  
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6 Discussion 
In this thesis, research was carried out on the influence of combined therapies, 
compared with treatments using mono-therapies, on the growth of tumors in immune-
suppressed mice that have been injected with adenocarcinoma cells. The results show a 
reduction in tumor growth and an alleged increase in apoptosis, as a decrease of the 
active rate of cell division. 
In addition to the study of the target parameters (tumor growth, active cell division, and 
blood vessels), the following receptors have been studied: cKIT, Flt-1, EGFR, PDE5, 
PDGFR-alpha, and PDGFR-beta. RET, CSF-1R, Flt3, KDR, and VEGFR3 were also 
studied at the mRNA level. 
 
6.1 Expression profile of tyrosine kinase receptor in tumor, 
monocytes, macrophages, lymphocytes and fibroblasts 
As mentioned above, Flt-1 belongs to the VEGF family. It has been documented 
numerous times in science that Flt-1 is highly expressed in tumor tissue (PMID: 
21592963; Review Expert Onion). Also on the mRNA level an expression of Flt-3 and 
VEGFR3 appears, two additional representatives of the VEGF family. In the results we 
have obtained, it is apparent in all groups that those that have been treated with an 
inhibitor, or a combination of inhibitors, have had a minimal expression of Flt-1. It is 
known from other studies that PDE5 also has a deterministic influence on VEGF, and 
consequently on angiogenesis. A therapy with sildenafil has shown an increase in 
angiogenic activity. (PMID: 17585066 Sildenafil promotes ischemia-induced 
angiogenesis through a PKG-dependent pathway). 
It has been proven that the VEGF pathway plays a crucial role in the treatment of other 
types of tumor. Of particular importance is the treatment of renal cell carcinoma, 
NSCLC, mamma and colorectal cancer where the usage of medication, such as sunitinib 
or sevacicumab, results as neutralized antibodies for VEGF (Hurwitz 2004, PMID: 
12636887 Miller 2003, PMID: 20085937 Sandler, PMID: 21318618, Development of 
second-generation VEGFR tyrosine kinase inhibitors: current status).  
Another conclusion to be drawn from the present study is that the VEGF family, 
represented by Flt-1, plays a highly influential role in tumor growth. Surprisingly, only 
a scant amount of Flt-1 has been detected in both combined therapies as well as in the 
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mono-therapy with sorafenib. Sunitinib and sildenafil as mono-therapies reduce the 
density of receptors significantly; in combination, they are even more effective. 
As already described, sildenafil has an influence on different growth factors which 
affect angiogenesis as well as the inhibitors of the above-mentioned proliferation 
processes, such as the VEGF pathway. 
A further point of interest is the role of PDGFR-beta. As mentioned above, the growth 
factor receptor PDGFR-beta is a tyrosine kinase receptor. The downstream receptor 
signalling pathways influence angiogenesis, proliferation and the survival of the cell. 
It is known from other studies that PDGF-beta and its receptor is highly expressed in 
various types of tumors, and that it plays a role in their development, for example 
chronic myelomonocytic leukaemia (CMML) and Ewing‟s sarcoma (PMID: 8962143 
PDGFR beta Carroll 1996, PMID: 12700668 Uren PDGFR-beta Ewing). In the present 
study PDGFR-beta seems to play a crucial role concerning the size of the tumor. For the 
three groups that have kept the original size most constantly (sorafenib in the mono-
therapy and the two combination groups), we found barely any expressions of PDGF-
beta receptors. On a mRNA level it appears that PDGFR-beta is more prominent in cell 
forms of the tumor stroma, but also on isolated A549 cells, which would explain the 
strong occurrence even in tumor tissue. 
The related PDGF-alpha receptors appear to play a less important role in tumorigenesis. 
Their expression is reduced through the inhibitors applied. Surprisingly, the 
combination groups show a similar presence as sildenafil in mono-therapy. Sorafenib 
has the strongest influence. For the receptor cKIT, the combination sunitinib + sildenafil 
resulted in the strongest decrease in receptor density; however, the rest of the inhibitor 
groups have also caused a decrease in receptor density. A study analysing the factors 
PDGFR-alpha, PDGFR-beta and cKIT focusing on chordoma showed that although 
PDGFR-beta was highly expressed, PDGFR-alpha and cKIT were less expressed, with 
the conclusion that through a with imatinib (also a tyrosine kinase inhibitor), all three 
receptors together achieved the desired effect (PMID: 17145809 Tamborin PDGFR-
beta, alpha und cKIT). One can assume in this study that it is not just one factor that has 
an influence on tumor growth, but several that work together. The influence also varies 
from one inhibitor to another; different combinations of inhibitors produce different 
results. 
EGFR is another important factor concerning tumor growth. This study shows that 
exclusive donation of sildenafil results in significantly distinct density of receptors for 
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EGF (when compared with the two control groups), but the remaining inhibitors show 
an even lower density of receptors. It is known that tumor cells produces EGF-family 
ligands to stimulate the proliferation of tumor cells and their expressions of EGFR by 
autocrine and paracrine stimulation (PMID: 16489018 Tumour endothelial cells 
express...). 
All in all, for the sunitinib + sildenafil groups, Flt-1, PDGFR-beta, EGFR, and cKIT all 
showed little to no expression in the density of their receptors in tumor tissue of 
sunitinib + sildenafil groups acquired on the last day of measurement. Sorafenib, as a 
monotherapy, obtained good results in reducing the density of the receptors; however, 
there was also a significantly low density of PDGFR-alpha. This hypothesizes that 
PDGFR-alpha plays a less important role in the increase of the volume of the tumor. 
 
6.2 In vivo effects of the PDE5 inhibitor sildenafil together with 
multikinase inhibitor sunitinib or sorafenib in the 
adenocarcinoma mouse model 
The combination sorafenib + sildenafil as well as the combination sutent + sildenafil 
showed almost minimal growth increase of the injected tumor cells during the course of 
the study. It should be noted that sorafenib, when used in monotherapy until day 16 
after the start of the experiment, shows almost the same average values as when used in 
combination with sildenafil. Likewise when compared with the other combination 
groups. 
In contrast, sildenafil, when used in mono-therapy, shows an increase on the same level 
as those in the combined therapy groups and sorafenib, up to day 12. After day 12, there 
is an increase in the volume of the tumor, similar to the monotherapy with sunitinib. 
Sildenafil is generally known as a specific inhibitor that affects an increase in the intra-
cellular cGMP concentrations, and thereby induces vasodilation (Lugnier et al., 1986, 
Schoeffter et al., 1987). In Germany it is approved for the treatment of pulmonary 
hypertension due to its efficacy since 2006 (Journal med., 09.11.2005). 
When combined with the multi-kinase inhibitors studied, it is obvious that the active 
agent only has an effect on the smooth muscle cells in the blood vessels of the tumor 
tissue and that the influence on the other growth factors and receptors is attributable to 
the combination compound. On the mRNA level, there is only a scant amount of PDE5a 
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in isolated A549 cells; however, it is evenly distributed in the remaining cells of the 
tumor stroma, human donor lung, and tumor tissue. It is interesting to note, that the 
immunohistochemical quantification shows that sildenafil, in addition to its well-known 
influence on PDE5 also shows a significant influence on Flt-1, PDGFR-beta and PCNA. 
Furthermore, sildenafil also shows an effect on EGFR and PDGFR-alpha, though this is 
noticeably weaker than those effects caused by the rest of the therapeutics. In other 
studies, PDE5 was described as a determinant in the proliferation of endothelial cells 
that created safe and stable conditions for angiogenesis by down regulation in the 
microvascular endothelium. (PMID: 19028977, Type 5 PDE expression is a critical 
determinant of the endothelial cell angiogenic phenotype). 
In the immunohistochemical quantification of the vWF + alpha actin staining (which 
make the blood vessels visible), it becomes apparent that sildenafil and sunitinib show 
the least amount of blood vessels in mono-therapies; the most are shown when sunitinib 
and sildenafil are combined. 
The smallest number of active cell divisions, however, occurs with sunitinib as well as 
with sildenafil in mono-therapy. Sorafenib shows a slightly higher rate of cell division, 
and both combination groups show the highest rate. This might lead to the hypothesis 
that tumor growth consists of a combination of active rates of cell divisions and 
vascularisation. 
It is known from several studies that tumor growth proceeds slowly and moderately 
before vascularisation begins and continues rapidly and almost exponentially after 
vascularisation (PMID: 1688381 What is the evidence that tumours are angiogenesis 
dependent?). 
The best outcome, defined as the smallest tumor growth, could be demonstrated for the 
combination sunitinib + sildenafil, even if, interestingly, the counted sections of vessels 
are the highest, almost as high as in the two untreated control groups. 
The smaller the tumor, the better the vascularisation. This hypothesizes that there could 
be a coherence between the effect of the specific therapy at the designated destination 
and the predominant vascularisation. It is debatable whether the antiproliferative effects 
of the combination sunitinib + sildenafil is stronger than the proangiogenetic effect of 
sildenafil on its own. 
Based on the measured growth of the tumor, it is apparent that combined therapy is the 
most efficacious. The question that arises, as considered previously in connection with 
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vascularisation, is what specific influence the various inhibitors and their combinations 
have on the studied receptors. 
 
6.3 Analysis of morphology, angiogenesis and proliferation in tumor 
tissue 
On the mRNA level the tyrosin kinase receptors Flt-1, EGFR, PDGF-alpha, PDGFR-
beta, RET, CSF-1R, Flt3, cKIT, KDR, and VEGFR3 as well as the specific receptor 
PDE5a were examined concerning their appearance in different tumor tissues and cell 
kinds. The following were examined: A549 cells bred in an isolated culture medium; 
tumor tissues samples which had been injected with A549 cells in nude mice with no 
inhibitor treatment; human fibroblasts; monocytes; macrophages; lymphocytes; and 
human-donor lung tissue. 
Further the study focused on the tyrosine kinase receptors Flt-1 and KDR. Interestingly 
all the examined factors were present in the tissues tested, with the exception of Flt-1 
and KDR.  
There have been no expressions of Flt-1 in cultivated A549 cells. For the rest of the 
tissues and cell types, it is possible to detect Flt-1 with the help of qPCR. This suggests 
that whilst the A549 cells themselves may not have receptors for Flt-1, it is quite likely 
that the tumor stroma do. It is understood that „tumor stroma‟ refers to the tissue around 
the individual tumour cells. It has been proven that a tumor needs its stroma to interact 
(PMID: 17554513 The participation of mesenchymal stem cells in tumour stroma 
formation and their application as targeted-gene delivery vehicles). In this stroma, the 
following are located: monocytes, macrophages, mast cells, tumor-associated 
fibroblasts, and other immune cells (Review Expert Onion, Raj). It was not possible to 
continue with the immunohistochemical detection of KDR, as the markers used by us 
were not able to leave a visible staining of the tissue samples. 
Although it was not possible to investigate additional factors, it should be possible, in 
further studies, to examine these factors (cKIT, RET, CSF-1R, Flt3 and VEGFR3), their 
occurrence, and their influence on the growth of the tumor and vascularisation in 
NSCLC. 
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6.4 Analysis of the role of angiogenesis in tumor tissue growth 
Past research has shown that there is a connection between the size of the tumor and the 
vascularisation. Up to a certain point, the tumor is well supplied with blood by the 
surrounding tissue. Once the tumor has become too big, its own blood supply becomes 
necessary. (PMID: 8756718 Patterns and emerging mechanisms of the angiogenic 
switch during tumourigenesis). A good blood flow favors the growth of the tumor 
without ischemia. In the present study necrotic parts were found in the sections of the 
tumor of the control group as well as in the placebo group. The tumor appears to grow 
quickly, and from day 16 onwards, the growth appears to be almost exponential; 
however, from a certain tumor volume onwards, it appears that the development of the 
blood vessels is not able to keep up with the growth, and parts of the tumor decay. Thus, 
a small tumor does not need its own blood supply. Nevertheless, it is apparent in this 
study that the group that has, on average, the smallest and most constant tumor volume 
is also the one that has the highest number of sections of blood vessels. 
This begs the question whether the receptors, which were the least adjusted in this group 
compared to the control groups, had the most influence on angiogenesis, in particular 
PDGFR-alpha. This could be investigated in detail in future studies. 
It also seems dubious whether sildenafil, with its pro-angiogenic effects, is superior to 
sunitinib, with its anti-angiogenic effects. When used in monotherapy, both show a 
similar high number of sections with blood vessels. 
It is a fact that a combined therapy of sunitinib + sildenafil results in a clearly reduced 
tumor volume. A smaller non-growing tumor in the body would increase the length of 
survival for a patient suffering from NSCLC. Both medications are, as already stated 
above, in use as therapeutic agents for humans. Further studies could probably 
determine to what extent this combination can be used as a therapy for NSCLC. It is 
still not clear why this combination is the most successful, even though, as had been 
expected, the density of amount of number of sections with blood vessels has decreased. 
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7 Summary 
Lung cancer is still the leading cause of death amongst the various types of cancers. 
This study researched the influence of a combined therapy, consisting of a multi-kinase 
inhibitor and a specific phosphodiesterase 5 inhibitor, compared with that of a single 
inhibitor used in mono-therapies and compared with that in a placebo. 
On the day the experiment commenced, all the animals received a subcutaneous 
injection of isolated A549 cells just above the muscle of the right buttock. 
Each of the seven animal test groups consisted of 6-10 laboratory animals (nude mice). 
For the duration of the experiment of 28 days, the animals were treated with different 
inhibitors in the form of oral medication: sildenafil, a specific PDE5 inhibitor, sorafenib 
and sunitinib as multi-kinase inhibitors, the combined therapy groups sorafinib + 
sildenafil and sunitinib + sildenafil, the placebo groups (these laboratory animals 
received an oral dose of methylcellulose), and finally the control group – there was no 
intervention with these animals. 
The animals received the same dosage of medication. The size of the tumor was 
measured every four days. 
The largest increase in volume occurred, as expected, in the control and the placebo 
groups. The smallest increase in volume occurred in the combined-therapy groups. The 
most constant was, however, for the combination of sunitinib + sildenafil. 
The mRNA expression of individual growth factor receptors from tissues of the control 
group was examined with the help of real-time PCR. In order to capture the influence of 
tumor stroma, the following were also examined: human fibroblasts, monocytes, 
macrophages, lymphocytes, donor lung tissue, and, for comparison, isolated and 
cultivated A549 cells. The receptors cKIT, RET, CSF-1R, Flt3, PDGF-alpha, PDGF-
beta, EGF, VEGF3 and also the receptor for PDE5a showed an expression in every 
sample examined. Flt.1 and KDR showed no expression in isolated A549 cells; 
however, they did show expressions in the rest of the tissues. 
Furthermore, some of these factors were compared among themselves and examined for 
their expression in the tumors of the individual groups by means of 
immunohistochemical quantification. At the end of the experiment, the resulting tumor 
was dissected from the attached tissue and, after the usual preparation, cut for the 
immunohistochemical examination. We could demonstrate a decrease in the expression 
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of the various growth factor receptors that were inhibited. In particular, PDGFR-beta, 
Flt-1 and EGFR showed a significant decline in the density of receptors. 
Additionally, the active rate of cell division (PCNA) and the existing section of the 
vessels were stained and compared with one another. It was interesting to note, that the 
one with the smallest increase in tumor volume had the largest number of vessel 
sections and a slightly higher active rate of cell division, in comparison to the mono-
therapy group. 
The combined therapy of a multi-kinase inhibitor and the specific PDE5 inhibitor 
appears to be a good therapy option for NSCLC, as the tumor growth is delayed and so 
the chance of survival increased. The influence of the factors studied provided no 
detailed information about the mode of action effective in this kind of therapy, in 
particular with regards to angiogenesis. This needs to be examined in further studies. 
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8 Zusammenfassung 
Lungenkrebs ist noch immer die weltweit führende Krebserkrankung mit Todesfolge. 
Diese Studie untersuchte den Einfluss einer Kombinationstherapie, bestehend aus einem 
Multikinaseinhibitor und einem spezifischen Phosphodiesterase-5-Inhibitor im 
Vergleich mit den einzelnen Inhibitoren als Monotherapiegabe und im Vergleich zu 
einer Placebogabe bzw. einer Versuchsgruppe ohne Intervention. 
Am Tag des Versuchsbeginns wurde allen Tieren isolierte A549 Zellen subkutan 
oberhalb des Muskels am rechten Hinterlauf injiziert. 
Die sieben Versuchstiergruppen bestanden aus den jeweils 6-10 Versuchstieren 
(Nacktmäuse) und wurden während der Versuchsdauer von 28 Tagen mit den 
unterschiedlichen Inhibitoren als orale Medikation behandelt. Die Behandlungen 
erfolgten mit Sildenafil, als spezifischer PDE5-Inhibitor, Sorafenib und Sunitinib als 
Multikinaseinhibitoren, die Kombinationentherapiegruppen bestehend aus Sorafenib + 
Sildenafil und Sunitinib + Sildenafil, des Weiteren die Placebogruppe. Diese 
Versuchstiere bekamen Methylcellulose oral verabreicht und zuletzt die Kontrollgruppe, 
an der keine Intervention stattgefunden hat. 
Die Tiere erhielten jeden Tag die gleiche Medikamentendosis, jeden 4. Tag erfolgte 
eine Messung der Tumorgröße. 
Die größte Volumenzunahme zeigte sich, wie zu erwarten war, bei der Kontroll- und bei 
der Placebogruppe, die kleinste Volumenzunahme zeigte sich bei den beiden 
Kombinationstherapiegruppen, am konstantesten jedoch bei der Kombination aus 
Sunitinib + Sildenafil. 
An Tumorgewebe aus der Kontrollgruppe wurde die mRNA-Expression einzelner 
Wachstumsfaktorenrezeptoren untersucht. Um den Einfluss des Tumorstroma zusätzlich 
zu erfassen, wurden humane Fibroblasten, Monozyten, Makrophagen, Lymphozyten 
und humanes Donorlungengewebe und zum Vergleich isolierte und angezüchtete A549-
Zellen untersucht. Die Rezeptoren cKIT, RET, CSF-1R, Flt3, PDGF-alpha, PDGF-beta, 
EGF, VEGF3 sowie der PDE5a-Rezeptor waren in allen untersuchten Proben 
exprimiert, Flt-1 und KDR zeigten keine Expression in isolierten A549-Zellen, jedoch 
in den übrigen Gewebearten. 
Weiter wurden einige dieser Faktoren mit Hilfe immunhistochemischer Quantifikation 
auf ihre Expression in den Tumoren der einzelnen Gruppen untersucht und 
untereinander verglichen. Nach Versuchsende wurden dafür die entstandenen Tumore 
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von dem darunterliegenden Gewebe abpräpariert und nach üblicher Vorbereitung für 
die Immunhistochemie aufgeschnitten. Es zeigte sich eine Abnahme der Expression von 
diversen Wachstumfaktorrezeptoren unter Inhibition. Vor allem PDGFR-beta, Flt-1 und 
EGFR zeigten eine signifikante Abnahme der Rezeptorendichte. 
Desweiteren wurden die aktive Zellteilungsrate (PCNA) und die vorhandenen 
Gefäßanschnitte (vWF+alpha actin) angefärbt und untereinander verglichen. 
Interessanterweise zeigte sich bei der geringsten Volumenvergrößerung des Tumors die 
größte Anzahl von Gefäßanschnitten und eine etwas höhere aktive Zellteilungsrate im 
Vergleich zu den Monotherapiegruppen. 
Die Kombinationstherapie aus einem Multikinaseinhibitor und dem spezifischen PDE5-
Inhibitor scheint eine gute Therapieoption für NSCLC zu sein, da das Tumorwachstum 
verzögert wird und damit die Überlebenswahrscheinlichkeit steigt. Der Einfluss auf die 
untersuchten Faktoren konnte jedoch keinen sicheren Aufschluss über den genauen 
Wirkmechanismus dieser Therapie geben, besonders in Hinblick auf die Angiogenese. 
Dies sollte in weiterführenden Studien näher untersucht werden. 
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10 Abbreviations 
A549 cells adenocarcinoma 549 cells 
AC adenylyl cyclase 
ANP atrial natriuretic peptide 
ATP adenosine-5'-triphosphate  
BNP b-type natriuretic peptide 
cAMP cyclic adenosine monophosphate 
cGMP cyclic guanosine monophosphate 
CMML chronic myelomonocytic leukaemia 
COPD chronic obstructive pulmonary disease  
CT computed tomography 
DGAUM 
Deutsche Gesellschaft für Arbeitsmedizin und 
Umweltmedizin e.V. 
DMEM Dulbeccos Modified Eagle Medium 
DMSO  dimethyl sulfoxide  
DNA desoxyribonucleic acid  
dNTP desoxyribonucleosidetriphosphate 
dsDNA double stranded DNA 
EGF epidermal growth factor 
EPAC exchange protein activated by cAMP 
EPAC cAMP-activated exchange factors 
ERK extracellular signal regulated kinases 
EtOH ethanol 
FCS fetal calf serum 
FLT fms-like tyrosine kinase  
GDP guanosine diphosphate  
GEF guanine nucleotide exchange factors 
GIST gastrointestinal stroma tumor 
GTP guanosine triphosphate  
HCC hepatocelllular carcinoma 
HE haematoxilin-eosin staining 
HRPT hypoxynthinephophoribo-syltransferase 
i.e.  for example 
KCl potassium chloride  
KDR kinase insert domain receptor 
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MAPK mitogen-activated protein 
mRNA messenger RNA  
NaCl sodium chloride  
NO nitric oxide 
NP natriuretic peptides 
NSCLC non-small-cell lung carcinoma 
PBS phosphate buffered saline  
PCNA proliferating cell nuclear antigen  
PCR polymerase chain reaction  
PDE phosphodiesterase 
PDGF platelet-derived growth factor 
pGC particulate guanylyl cyclase 
PKA protein kinase A 
PPi pyrophosphate 
qPCR quantitative polymerase chain reaction  
RET ret-protooncogen 
RNA ribonucleic acid  
RT reverse transcriptase 
RTK receptor tyrosine kinase 
r.t. room temparature 
SCLC  small-cell-lung carcinoma 
sGC soluble guanylyl cyclase 
SMBD small molecule binding domains 
TGF transforming growth factor 
TKR tyrosine kinase receptor  
VEGF vascular endothelial growth factor 
vWF von Willebrand factor  
WHO World Health Organisation 
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